CD8A and neoplasm: First, the increased number of activated tumor-specific CD8+ T cells resulting from the presence of the primary tumor releases more tumor neoantigens when killing tumor cells, and these antigens are presented to intratumor-specific effector T cells at different sites—including the primary site, metastases, and the circulatory system—to activate a broad and powerful specific antitumor immune response and immune memory.